Know Cancer

forgot password

A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1/Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma

Thank you

Trial Information

A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

1. Males or females, age 18 years or older.

2. A diagnosis of MM and documentation of relapsed or relapse/refractory status
following at least 1 prior therapy and a maximum of 4 prior regimens.

3. Patients with measurable disease defined as at least one of the following these
baseline laboratory studies for determining eligibility must be obtained within 21
days prior to enrollment):

1. Serum M-protein ≥ 0.5 g/dl (≥ 5 g/l)

2. Urine M-protein ≥ 200 mg/24 h

3. Serum free light chains (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥100 mg/l)
and an abnormal serum free light chain ratio (< 0.26 or > 1.65)

4. Biopsy proven plasmacytoma (should be measured within 28 days of first study
drug administration). Prior biopsy is acceptable.

5. If the serum protein electrophoresis is unreliable for routine M-protein
measurement, quantitative immunoglobulin levels on nephrolometry or turbidometry
will be followed.

4. Patient has an Eastern Cooperative Oncology Group (ECOG) ≤ 2 OR Karnofsky

- 60% performance status (PS) (Appendix 13-2).

5. Predose mean QTc ≤ 450 msec or mean QTc Fridericia's Correction (QTcF)on Day 1(cycle
1 or cycle 0 if applicable) must be ≤ 450 msec.

6. Females of childbearing potential (FCBP): a female of childbearing potential is a
sexually mature woman who: 1) has not undergone a hysterectomy or bilateral
oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive
months). Pregnancy status in women of childbearing potential must be confirmed by
serum β-hCG at screening. Pregnancy testing is not required for post-menopausal or
surgically sterilized women. FCBP must use acceptable forms of birth control or agree
to abstain from heterosexual intercourse while participating in the study and for 90
days following the last dose of study drug. Men must agree to use a latex condom
during sexual contact with a FCBP even if they have had a successful vasectomy while
participating in the study and for 90 days following the last dose of study drug.

7. Voluntary, written informed consent before performance of any study-related procedure
not part of routine medical care with the understanding that consent may be withdrawn
by the patient at any time without prejudice to future medical care.

8. Ability to understand the purpose and risks of the study and provide signed and dated
informed consent and authorization to use protected health information (in accordance
with national and local patient privacy regulations).

9. Must be able to take and retain oral medications.

10. Inclusion Clinical Laboratories Criteria The following laboratory results must be met
within 7 (+3 days if necessary for holiday/scheduling conflicts) days of first study
drug administration:

1. Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 10^9/L) (Growth factors
cannot be used within 14 days of first study drug administration);

2. Platelet count ≥ 50,000 cells/dL (50 x 109/L);

3. Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L);

4. Serum AST or ALT within normal limits;

5. Total bilirubin within normal limits;

6. Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault calculation);

7. Serum creatinine ≤1.5 x ULN (correction with hydration and re-testing is
permitted)(values ≥ 1.5 X ULN may be acceptable if improved to < 1.5 x ULN, with
hydration and/or attributable to progressing MM);

8. Serum calcium (ionized or corrected for albumin) ≥ 2.0 mmol/L (8.0 mg/dL or 1.0
mmol/L ionized calcium) to ULN. Treatment of hypercalcemia or hypocalcemia is
allowed and patient may enroll if serum calcium returns to > 2.0 mmols/L to ULN
with standard treatment

9. Serum potassium and magnesium within normal limits (correction with
supplementation is permitted);

10. HgbA1c of ≤ 7%;

11. Fasting glucose of ≤126 mg/dL (7.0 mmol/L). A diagnosis of Type II diabetes
mellitus is permitted if > 4 weeks since diagnosis and well controlled.
Concurrent non-insulinotropic antihyperglycemic therapy is permitted if the dose
has been stable for 8 weeks.

11. Resolution of prior toxicities associated with a prior treatment to

- grade 1.

Exclusion Criteria:

1. Patients refractory or intolerant to bortezomib are not permitted (Refractory =
non-responsive/progressed on therapy or within 60 days of bortezomib) on phase 2 part
of the study only.

2. Diagnosed or treated for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

3. Patient has received other investigational drugs or chemotherapy within 21 days or
approved anti-myeloma therapy including steroid therapy within 14 days prior to first
study drug administration.

4. History (within the last 6 months) of significant cardiovascular disease unless the
disease is well-controlled. Significant cardiac disease includes but is not limited
to second/third degree heart block; clinically significant ischemic heart disease;
superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart
failure of New York Heart Association (NYHA) Class II or worse. History of arrhythmia
(multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy,
ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or
requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic
sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation
controlled by medication are not excluded;

5. Mean QTc interval ≥ 450 msec or QTcF interval > 450 msec at screening;

6. Prior autologous, peripheral stem cell transplant within 12 weeks of the first dose
of study drug;

7. Daily requirement for corticosteroids (except for inhalation corticosteroids);

8. Patients with evidence of mucosal or internal bleeding and/or platelet transfusion
refractory (i.e., unable to maintain a platelet count ≥ 50,000 cells/dL);

9. Known active infection requiring parenteral or oral anti-infective treatment.

10. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or
confuse follow-up evaluation.

11. Use of any medical conditions that, in the Investigator's opinion, would impose
excessive risk to the patient. Examples of such conditions include any pre-existing
kidney disease (acute or chronic, unless renal insufficiency is felt to be secondary
to MM), hypertension, active seizure disorder or pulmonary diseases that would impose
excessive risk to the patient.

12. Patient has hypersensitivity to any of the components of study drugs;

13. Known HIV or active hepatitis B or C viral infection;

14. Diabetes mellitus currently requiring insulin or insulinotropic therapy or prior
history of steroid induced diabetes ;

15. History of cerebrovascular accident (CVA) within 6 months prior to registration or
that is not stable;

16. Prior therapy with an IGF-1R inhibitor;

17. Use of drugs that have a risk of causing QT interval prolongation and/or have a known
risk of causing Torsades de Pointes (TdP) before 14 days or the recommended 5
half-life washout period elapses (as indicated in Appendix 13-6), which ever is
longer prior to Cycle 1 Day 1 dosing;. Drugs that have a known risk of causing TdP
can be found on ( pros/drug-lists/bycategory.cfm);

18. Use of strong/moderate CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other
less potent CYP1A2 inhibitors/inducers are not excluded (see appendix 13-9)

19. Gastrointestinal abnormalities, including bowel obstruction, inability to take oral
medication, requirement for intravenous (IV) alimentation, active peptic ulcer or
prior surgical procedures or bowel resection or other poorly controlled
gastrointestinal disorders that could affect the absorption of study drug (eg,
Crohn's disease or ulcerative colitis);

20. Peripheral neuropathy ≥ grade 2;

21. Significant liver disease or metastatic disease to the liver;

22. History of amyloid, plasma cell leukemia or CNS involvement.

23. Prior radiation therapy or major surgical procedure within 4 weeks of the first dose
of study treatment (this does not include limited course of radiation used for
management of bone pain).

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose of the combination of ASP7487 (OSI-906) with Velcade and Dexamethasone

Outcome Description:

Phase 1: To determine the maximum tolerated dose (MTD) of ASP7487 (OSI-906) administered in combination with the recommended dose and schedule of bortezomib and dexamethasone; Phase 2: To evaluate the antitumor activity of ASP7487 (OSI-906) in combination with bortezomib and dexamethasone at the MTD established from the Phase 1 component.

Outcome Time Frame:

It is estimated that it will take approximately 3-5 months determine MTD. The efficacy analysis could take upto 2.5 years after the activation date of the study to be completed.

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

September 2012

Completion Date:

December 2016

Related Keywords:

  • Multiple Myeloma
  • Relapsed or relapse/refractory Multiple Myeloma following at least 1 prior therapy and a maximum of 4 prior regimens.
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



University of Chicago Medical Center Chicago, Illinois  60637